Literature DB >> 18981566

Inhibition of the epstein-barr virus lytic cycle by andrographolide.

Tsuey-Pin Lin1, Shih-Ying Chen, Pin-Der Duh, Li-Kwan Chang, Yen-Ni Liu.   

Abstract

Andrographis paniculata NEES is a medicinal plant that is commonly used in Asia. This work demonstrates that 25 microg/ml of ethanolic extract from A. paniculata (EEAP) and 5 microg/ml of andrographolide, a bioactive compound in EEAP, effectively inhibit the expression of Epstein-Barr virus (EBV) lytic proteins, Rta, Zta and EA-D, during the viral lytic cycle in P3HR1 cells. Transient transfection analysis revealed that the lack of expression of Rta, Zta and EA-D is caused by the inhibition of the transcription of BRLF1 and BZLF1, two EBV immediate-early genes that encode Rta and Zta, respectively. This study finds that the inhibition prevents the virus from producing mature viral particles. Meanwhile, andrographolide is not toxic to P3HR1 cells when the concentration is below 5 microg/ml, indicating that the compound is potentially useful as an anti-EBV drug.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981566     DOI: 10.1248/bpb.31.2018

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  31 in total

1.  Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells.

Authors:  Jin-Ching Lee; Chin-Kai Tseng; Kung-Chia Young; Hung-Yu Sun; Shainn-Wei Wang; Wei-Chun Chen; Chun-Kuang Lin; Yu-Hsuan Wu
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

2.  Andrographolide protects against cigarette smoke-induced oxidative lung injury via augmentation of Nrf2 activity.

Authors:  S P Guan; W Tee; D S W Ng; T K Chan; H Y Peh; W E Ho; C Cheng; J C Mak; W S F Wong
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

3.  Neuroprotective effects of andrographolide in a rat model of permanent cerebral ischaemia.

Authors:  Su Jing Chan; W S Fred Wong; Peter T H Wong; Jin-Song Bian
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

4.  Inhibitory activities of microalgal extracts against Epstein-Barr virus DNA release from lymphoblastoid cells.

Authors:  Yih-Yih Kok; Wan-Loy Chu; Siew-Moi Phang; Shar Mariam Mohamed; Rakesh Naidu; Pey-Jiun Lai; Shui-Nyuk Ling; Joon-Wah Mak; Patricia Kim-Chooi Lim; Pauline Balraj; Alan Soo-Beng Khoo
Journal:  J Zhejiang Univ Sci B       Date:  2011-05       Impact factor: 3.066

5.  Whole transcriptome analysis identifies full-length genes for neoandrographolide biosynthesis from Andrographis alata, an alternate source for antiviral compounds.

Authors:  Gupta Tanuja; Madasamy Parani
Journal:  Gene       Date:  2022-10-18       Impact factor: 3.913

6.  Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian).

Authors:  Wen-Wan Chao; Bi-Fong Lin
Journal:  Chin Med       Date:  2010-05-13       Impact factor: 5.455

Review 7.  Chinese medicines and bioactive compounds for treatment of stroke.

Authors:  Thanasekaran Jayakumar; Antoinet Ramola Elizebeth; Ting-lin Yen; Joen-rong Sheu
Journal:  Chin J Integr Med       Date:  2014-07-10       Impact factor: 1.978

8.  Andrographolide plays an important role in bleomycin-induced pulmonary fibrosis treatment.

Authors:  Jia-Ning Yin; Ya-Nan Li; Yang Gao; Shi-Bo Li; Jian-Dong Li
Journal:  Int J Clin Exp Med       Date:  2015-08-15

9.  Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial.

Authors:  Xin-Yi Zhang; Lang Lv; Yu-Long Zhou; Liang-Dong Xie; Qin Xu; Xiao-Fan Zou; Yan Ding; Jie Tian; Jia-Liang Fan; Hai-Wei Fan; Yi-Xi Yang; Xiao-Qun Ye
Journal:  Phytother Res       Date:  2021-05-12       Impact factor: 6.388

10.  Experimental and Clinical Pharmacology of Andrographis paniculata and Its Major Bioactive Phytoconstituent Andrographolide.

Authors:  Thanasekaran Jayakumar; Cheng-Ying Hsieh; Jie-Jen Lee; Joen-Rong Sheu
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.